<DOC>
	<DOCNO>NCT02496000</DOCNO>
	<brief_summary>Randomized , double-blind , placebo-controlled , parallel group study .</brief_summary>
	<brief_title>Phase II Safety Efficacy Study Oral ORMD-0801 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This multicenter , Phase II , randomize , double-blind , placebo-controlled , parallel group study . After appropriate screening , approximately 180 male female patient 33 study center treat study . Patients type 2 diabetes mellitus treat diet , exercise , untreated antidiabetic medication treat metformin monotherapy combination one antidiabetic drug ( exclude insulin ) eligible enrollment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>HbA1c ≥7.5 % naïve antidiabetic therapy ; ≥6.5 % ≤10 % metformin ≥1,500 mg daily ; ≥6.5 % ≤9.5 % monotherapy antidiabetic drug metformin ; ≥ 6.5 % ≤9.5 % metformin one antidiabetic drug ; ≥ 7.0 % metformin &lt; 1,500 mg daily . At time randomization , patient treat diabetes diet , exercise , metformin ( ≥1500 mg/day ; type regimen ) . Patients stable regimen metformin ( define metformin dose type ) least two week prior enter singleblind placebo runin period . Other antidiabetic agent use two week prior enter placebo runin period . Patients maximum tolerate dose ( MTD ) metformin 1,000 mg allow enter study . At Day 7 ( Visit 3 ) , patient HbA1c ≥ 6.5 % ≤10 % . Body Mass Index 25 40 kg/m2 , inclusive . Fasting blood glucose ≥ 126 mg/dL ( 8.3 mmol/L ) prior randomization Day 7 ( Visit 3 ) . For patient Day 7 ( Visit 3 ) fast blood glucose &lt; 126 mg/dL ≥ 115 mg/dL , Day 7 ( Visit 3 ) HbA1C ≥ 7 % ≤ 10 % , minimum 5 daily self monitor fast blood glucose check record patient diary average . If average value ≥ 126 mg/dL , patient may continue trial . Females childbearing potential must negative urine pregnancy test result screening . A negative urine pregnancy test must obtain Visit 2 Visit 4 ( prior randomization ) . Males females childbearing potential must use two method contraception ( double barrier method ) , one must acceptable barrier method time screen last study visit ( Day 43 ) . Patient &gt; 80 % compliance placebo run prior randomization . Patient ≥ 80 % glucose reading least two 24 hour period ( 6AM 6AM ) seven day CGM period . Patient perform ≥ 10/14 self monitor glucose level measurement placebo runin , prior randomization . Patients meet follow criterion eligible study . Presence clinically significant endocrine disease accord Investigator ( euthyroid patient replacement therapy include dosage thyroxine stable least six week prior Screening Visit ) . Clinical diagnosis Type 1 diabetes . Fasting blood glucose &gt; 260 mg/dL end Day 7/Visit 3 . For patient Day 07 ( Visit 3 ) fast blood glucose &gt; 260 mg/dL &lt; 300 mg/dL , Day 7 ( Visit 3 ) HbA1C ≥ 7 % ≤ 10 % , minimum 5 selfmonitored fast blood glucose check record patient diary average . If average value ≤ 260 mg/dL , patient may continue trial . Presence history cancer within past five year exception adequatelytreated localized basal cell skin cancer situ uterine cervical cancer . Laboratory abnormality screen include : 1 . Cpeptide &lt; 1.0 ng/mL . 2 . Positive pregnancy test female childbearing potential ( screen start runin period ) . 3 . Abnormal serum thyrotropin ( TSH ) level &gt; 1.5 time upper limit normal . 4 . Positive test hepatitis B surface antigen and/or hepatitis C antibody . 5 . Positive test HIV . 6 . Serum Cr &gt; 1.4mg/dl male , &gt; 1.3mg/dl female . 7 . Any relevant abnormality interfere efficacy safety assessment study drug administration . Use following medication : 1 . History use insulin great one week last six month use insulin last six week prior randomization . 2 . Administration antidiabetic drug metformin within four week prior randomization visit . Administration thyroid preparation thyroxine within six week prior screen visit . ( Patients stable thyroid replacement therapy great 6 week may enter study . ) Administration systemic longacting corticosteroid within two month prolong use ( one week ) systemic corticosteroid inhale corticosteroid within 30 day prior screen visit . Use medication know modify glucose metabolism decrease ability recover hypoglycemia oral , parenteral , inhaled steroid ( discuss ) , beta blocker ( exception beta blocker ophthalmic solution glaucoma ocular hypertension ) , immunosuppressive immunomodulating agent . History tobacco nicotine use excess two packs/day within ten week prior screen . Patient weight loss program maintenance phase , patient start approved non approve weight loss medication within eight week prior screen . Pregnancy breastfeed . Patient screen visit systolic blood pressure ≥160 mm Hg diastolic blood pressure ≥100 mm Hg Patients allow take BP medication long stable dose period four week prior screen visit . Patient , time signing informed consent , user recreational illicit drug recent history ( within last year ) drug alcohol abuse dependence . ( Note : Alcohol abuse include heavy alcohol intake define &gt; 3 drink per day &gt; 14 drink per week , binge drinking ) . Elevated liver enzyme ( alanine transaminase ( ALT ) , alanine aminotransferase ( AST ) , alkaline phosphatase ) great two time upper limit normal screening . Very high triglyceride level ( &gt; 500 mg/dL ) screening . Any clinically significant electrocardiogram ( ECG ) abnormality screen cardiovascular disease . Clinically significant cardiovascular disease include : 1 . History stroke , transient ischemic attack , myocardial infarction within six month prior screen , 2 . History currently New York Heart Associate Class IIIV heart failure prior screening , 3 . Uncontrolled hypertension define blood pressure ≥160 mmHg ( systolic ) ≥100 mmHg ( diastolic ) screening .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Diabetes Mellitus type 2</keyword>
	<keyword>Metformin</keyword>
	<keyword>oral insulin</keyword>
</DOC>